Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Portal vein embolization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Portal vein embolization. Displaying page 1 of 1.
    EudraCT Number: 2012-005375-14 Sponsor Protocol Number: TS-104 Start Date*: 2013-06-03
    Sponsor Name:Biocompatibles UK Ltd
    Full Title: A prospective randomized clinical trial on 90Yttrium trans-arterial radio-Embolization (Therasphere) vs. standard of care (sorafenib) for the treatment of advanced Hepatocellular carcinoma (HCC) ...
    Medical condition: Advanced Hepatocellular Carcinoma (HCC) with Portal Vein Thrombosis (PVT)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    17.0 10019805 - Hepatobiliary disorders 10036206 Portal vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019379-31 Sponsor Protocol Number: LIVERONE Start Date*: 2010-03-23
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Evaluation of epatic rigeneration after G-CSF administartion in patients undergoing embolization procedure or portal vein tying forecasting resective surgery for neoplasia.
    Medical condition: patients affected by colangiocarcinoma or hepatic metastasis for colon-rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017947 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001062-93 Sponsor Protocol Number: CRC-01 Start Date*: 2008-09-04
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Perioperative treatment with COI-E (capecitabine, oxaliplatin, irinotecan and cetuximab) of liver metastasis of colorectal carcinoma potentially resectable although at high risk of recurrences
    Medical condition: Patients affected by colorectal metastases to the liver only (stage IV-liver only) defined as potentially resectable although at high risk of recurrence according to INT-MILAN internal guidelines.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000798-31 Sponsor Protocol Number: NEMA-0027-018 Start Date*: 2007-03-02
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: Phase II randomized study of nemorubicin hydrochloride (PNU-152243A) or doxorubicin administered in adult patients with unresectable hepatocellular carcinoma
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000144-18 Sponsor Protocol Number: CDKO-125a-010 Start Date*: 2017-08-01
    Sponsor Name:Tiziana Life Sciences Plc
    Full Title: Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients with Unresectable or Metastatic Hepatocellular Carcinoma
    Medical condition: Uunresectable or metastatic hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 19:28:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA